121 results
424B3
SYRE
Spyre Therapeutics Inc.
15 May 24
Prospectus supplement
4:06pm
)
Three Months Ended
March 31,
Revenue:
Development fee and royalty
Total revenue
Operating expenses:
Research and development (1)
General … the treatment of inflammatory bowel disease through a research and development option agreement (“Paragon Agreement”) with Paragon Therapeutics (“Paragon
8-K
SYRE
Spyre Therapeutics Inc.
15 May 24
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
7:40am
April 2024. Previously, from 2020 to 2024, Dr. Milligan served as the Head of Research and Development of Organon & Co. and, from 2015 to 2020
8-K
EX-99.1
SYRE
Spyre Therapeutics Inc.
15 May 24
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
7:40am
at Aspira, Dr. Milligan served as the Head of Research and Development of Organon & Co. Previously, she served in key executive positions, including Senior
8-K
EX-99.1
SYRE
Spyre Therapeutics Inc.
9 May 24
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:11pm
placement of equity securities.
Research and Development (R&D) expenses: R&D expenses totaled $34.9 million for the first quarter of 2024 and $13.8 … , except share and per share amounts)
Three Months Ended
March 31,
Revenue:
Development fee and royalty
Total revenue
Operating expenses:
Research
POS AM
yg7uscwz
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
POS AM
vqtqs
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
POS AM
9nz9z5ooz
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
8-K
EX-99.1
r6p8nz
29 Feb 24
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:14pm